{"name":"HUTCHMED (China)","slug":"hutchmed","ticker":"HCM","exchange":"NASDAQ","domain":"hutch-med.com","description":"HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular ","hq":"Hong Kong / Shanghai","founded":0,"employees":"1796","ceo":"Weiguo Su","sector":"Oncology / China Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":12.54,"stockChange":-0.13,"stockChangePercent":-1.03,"marketCap":"$2.2B","metrics":{"revenue":548512000,"revenueGrowth":-16.5,"grossMargin":11.6,"rdSpend":148295000,"netIncome":456909000,"cash":71330000,"dividendYield":0,"peRatio":4.7,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Elunate patent cliff ($1.4B at risk)","drug":"Elunate","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"fruquintinib+sintilimab patent cliff ($2.2B at risk)","drug":"fruquintinib+sintilimab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Fluconazole 400 mg","genericName":"Fluconazole 400 mg","slug":"fluconazole-400-mg","indication":"Other","status":"phase_1"},{"name":"HMPL-760 planned dose 1","genericName":"HMPL-760 planned dose 1","slug":"hmpl-760-planned-dose-1","indication":"Other","status":"phase_2"},{"name":"Surufatinib in combination with Gemcitabine","genericName":"Surufatinib in combination with Gemcitabine","slug":"surufatinib-in-combination-with-gemcitabine","indication":"Other","status":"phase_1"},{"name":"HMPL-506","genericName":"HMPL-506","slug":"hmpl-506","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Elunate®","genericName":"Elunate®","slug":"elunate","indication":"Advanced or metastatic non-small cell lung cancer","status":"phase_2"},{"name":"HMPL-760","genericName":"HMPL-760","slug":"hmpl-760","indication":"Cholangiocarcinoma with FGFR2 fusion or rearrangement","status":"phase_3"},{"name":"R-GemOx","genericName":"R-GemOx","slug":"r-gemox","indication":"Advanced pancreatic cancer","status":"phase_3"}]}],"pipeline":[{"name":"Elunate®","genericName":"Elunate®","slug":"elunate","phase":"phase_2","mechanism":"Elunate is a small molecule inhibitor of the serine protease inhibitor, serpin family F member 5 (SERPINFB).","indications":["Advanced or metastatic non-small cell lung cancer","Advanced or metastatic gastric cancer"],"catalyst":""},{"name":"Fluconazole 400 mg","genericName":"Fluconazole 400 mg","slug":"fluconazole-400-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HMPL-760 planned dose 1","genericName":"HMPL-760 planned dose 1","slug":"hmpl-760-planned-dose-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Surufatinib in combination with Gemcitabine","genericName":"Surufatinib in combination with Gemcitabine","slug":"surufatinib-in-combination-with-gemcitabine","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HMPL-506","genericName":"HMPL-506","slug":"hmpl-506","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HMPL-760","genericName":"HMPL-760","slug":"hmpl-760","phase":"phase_3","mechanism":"HMPL-760 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["Cholangiocarcinoma with FGFR2 fusion or rearrangement","Urothelial carcinoma with FGFR alterations","Other solid tumors with FGFR genetic alterations"],"catalyst":""},{"name":"R-GemOx","genericName":"R-GemOx","slug":"r-gemox","phase":"phase_3","mechanism":"R-GemOx is a combination of gemcitabine and oxaliplatin, used to treat various cancers.","indications":["Advanced pancreatic cancer","Advanced biliary tract cancer"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"HUTCHMED Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"HUTCHMED reported its fourth quarter and full year 2023 financial results, with revenue of $143.4 million and a net loss of $144.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"HUTCHMED Announces Collaboration with Bristol Myers Squibb","summary":"HUTCHMED announced a collaboration with Bristol Myers Squibb to develop and commercialize its cancer therapies in China.","drugName":"","sentiment":"positive"},{"date":"2023-09-28","type":"regulatory","headline":"HUTCHMED Receives Approval for R-GemOx in China","summary":"HUTCHMED received approval from the National Medical Products Administration (NMPA) for its R-GemOx therapy in China.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-23","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPcFFnZnZwRFc4azFPLWNjdFZ5OHRMNWR6cGN1emJPZGZYd1FDemxSNXBqOGg2ZW1RYk96REV5ZzFZWk5HZTQ5NGE2dW1ZelVYb01yTUJqNWZ3NTBNYWRPMGJvTjFfRGNqNEsxNFJsajZWWlBCUlZmR29aUHdkUUc1SlNMNXdtRVB5TXYzSWkxVTJKd20yMWhaeGgxeVU2VU9TeVpFdGt6NU0xdnhBOTE1aTNCcw?oc=5","date":"2026-03-16","type":"pipeline","source":"Stock Titan","summary":"HUTCHMED (HCM) vests 19,913 LTIP shares for CEO Dr. Weiguo Su - Stock Titan","headline":"HUTCHMED (HCM) vests 19,913 LTIP shares for CEO Dr. Weiguo Su","sentiment":"neutral"},{"date":"2026-03-16","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-11","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPZXJiVzBwTTBuVWpOajRXd0JDVndCNkhzS2JlT09oNERsZnVabXozN1czZjF6STNSRzBEdmdPbGc2SE9pbjY3elVhckNILU1wZUF3NElEbUdRQ21STzM4Vm1kUHltYjFRVkptNHFkQmVqRE92dHBOajR4TGE4MGluUHl2NXFxTTNFS194OW5qU3gtYnEtWEt3dEFyRk9aRVZiOFRVbU9FOWxLdzNuYUVneDdYZ3VySnh0WGRaQW9SRkh6Y1lZbmIwaFhYZ1B5Vm5HUUlpeWxQaDItUU1R?oc=5","date":"2026-03-09","type":"deal","source":"globenewswire.com","summary":"HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China - globenewswire.com","headline":"HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China","sentiment":"neutral"},{"date":"2026-03-09","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-06","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"20-F filed with SEC: 20-F","headline":"Annual Report (20-F) Filed","sentiment":"neutral"},{"date":"2026-03-04","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-18","type":"pipeline","source":"simplywall.st","summary":"HUTCHMED (China) Limited's (LON:HCM) largest shareholders are retail investors who were rewarded as market cap surged UK£189m last week - simplywall.st","headline":"HUTCHMED (China) Limited's (LON:HCM) largest shareholders are retail investors who were rewarded as market cap surged UK","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOWG54ZGpXY2l3dFZ6NW82VEZXN3JKX3hKY1JiQmF0N09zM1lnUXVoVm1YT0Z4dnUyWUVsVFBzclRjSDZGeUZ5U1Vkanprb1ozeGlZZmxpb05tUnUxRTNwRTBqUmJ4MlYyOGt6ZDVJVVN3SGJRNDFHYTUwVFRLeGV6aWlPeGNRRzFSZ0RaLXFJV3k3RF9aTV9FcUpqb0hkSDRNOE44?oc=5","date":"2025-08-27","type":"pipeline","source":"BioCentury","summary":"Sanofi hires Kayath, veteran of BioMarin and Novartis, as CMO - BioCentury","headline":"Sanofi hires Kayath, veteran of BioMarin and Novartis, as CMO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQV1VuSHJTNVhxalQ2UjQwZHdGWEZKRGdDZjNEajNZY3RDVmVYQWY5VUdSM1AwZDFiNHFQSUw3YU1WUTJub29vcTRoeEU3NXhWREVyTWIxeHI2ZVdaaU1SSWNGbjZpejN0Nld6bzN2ZVdncEVpOE5zZkFyZDdkZVRvVThxZ3htZVdZenhaTVpKcFA4bUdlWlJ3?oc=5","date":"2025-03-19","type":"pipeline","source":"The Pharma Letter","summary":"Hutchmed and Innovent’s double act effective in advanced RCC - The Pharma Letter","headline":"Hutchmed and Innovent’s double act effective in advanced RCC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxNczZLeXhPbzBSNzctRVk3RjUwWlZlZHlucmQzRl9hMGpiWWxnV3dkTnZ1eWdveVAwb09PMmJXMzJKOG1PdnNlS1ItcTFEZFMyVjdoWXluUm1tRlRQS3BBSUhBcUtkZDFEbkhkOTdPeml1dEFKbjdRQmpJdEZ3QmhMalVsMWx4eUJvYmNBU08tTGtGWXJCWDd3ckoybXZydjVJQnhoN190cTFvckhaWHdZbS1QNWszdlp6SmlUSHdMNUF3NmJ0anc0VF9LMnFfZkdBcVRySVFkU2FFWTRWUHJQampTRGktWTloa2lwZjRNZlg2Wk1EdDM1cTIxaw?oc=5","date":"2025-01-01","type":"pipeline","source":"Quiver Quantitative","summary":"HUTCHMED Announces Divestment of 45% Stake in Shanghai Hutchison Pharmaceuticals to Focus on Innovative Medicines and R&D Pipeline - Quiver Quantitative","headline":"HUTCHMED Announces Divestment of 45% Stake in Shanghai Hutchison Pharmaceuticals to Focus on Innovative Medicines and R&","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiT0FVX3lxTE9BZjRnUmthVjdWWFJDY2EydE5kSkpIOXRNUzRyLXE3VUZNdjJYQVZhcFdpUHJfcF9VbmczdzZZalYwMm5vNWdzak13X2F1X3M?oc=5","date":"2023-08-17","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"Elunate","drugSlug":"fruquintinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"fruquintinib+sintilimab","drugSlug":"sintilimab","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":2200000000}],"drugCount":7,"phaseCounts":{"phase_2":2,"phase_1":3,"phase_3":2},"enrichmentLevel":3,"visitCount":5,"keyCompetitors":["BeiGene","Innovent Biologics","Zai Lab"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":426409000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":426409000,"period":"2022-12-31"},{"value":356128000,"period":"2021-12-31"},{"value":227976000,"period":"2020-12-31"},{"value":204890000,"period":"2019-12-31"}],"grossProfit":212163000,"grossProfitHistory":[{"period":"2025-12-31","value":212163000},{"period":"2024-12-31","value":281317000},{"period":"2023-12-31","value":453552000},{"period":"2022-12-31","value":115306000}],"rdSpend":148295000,"rdSpendHistory":[{"period":"2025-12-31","value":148295000},{"period":"2024-12-31","value":212109000},{"period":"2023-12-31","value":302001000},{"period":"2022-12-31","value":386893000}],"sgaSpend":103028000,"operatingIncome":-35700000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-35700000},{"period":"2024-12-31","value":-40610000},{"period":"2023-12-31","value":21509000},{"period":"2022-12-31","value":-406259000}],"netIncome":456909000,"netIncomeHistory":[{"period":"2025-12-31","value":456909000},{"period":"2024-12-31","value":37729000},{"period":"2023-12-31","value":100780000},{"period":"2022-12-31","value":-360835000}],"eps":2.65,"epsHistory":[{"period":"2025-12-31","value":2.65},{"period":"2024-12-31","value":0.2},{"period":"2023-12-31","value":0.6},{"period":"2022-12-31","value":-2.15}],"cash":71330000,"cashHistory":[{"period":"2025-12-31","value":71330000},{"period":"2024-12-31","value":153958000},{"period":"2023-12-31","value":283589000},{"period":"2022-12-31","value":313278000}],"totalAssets":1753097000,"totalLiabilities":501835000,"totalDebt":97893000,"equity":1237926000,"operatingCashflow":-64657000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-64657000},{"period":"2024-12-31","value":497000},{"period":"2023-12-31","value":219258000},{"period":"2022-12-31","value":-268599000}],"capex":-24148000,"capexHistory":[{"period":"2025-12-31","value":-24148000},{"period":"2024-12-31","value":-17933000},{"period":"2023-12-31","value":-32612000},{"period":"2022-12-31","value":-36664000}],"freeCashflow":-88805000,"dividendsPaid":null,"buybacks":0,"employees":1796,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":12.54,"previousClose":12.67,"fiftyTwoWeekHigh":19.5,"fiftyTwoWeekLow":12.42,"fiftyTwoWeekRange":"12.42 - 19.5","fiftyDayAverage":14.2,"twoHundredDayAverage":14.95,"beta":0.38,"enterpriseValue":9635284992,"forwardPE":24.1,"priceToBook":1.74,"priceToSales":3.93,"enterpriseToRevenue":17.57,"enterpriseToEbitda":-372.71,"pegRatio":0,"ebitda":-25852000,"ebitdaMargin":-4.7,"freeCashflow":-54012624,"operatingCashflow":-64657000,"totalDebt":97893000,"debtToEquity":7.8,"currentRatio":4.96,"returnOnAssets":-1.6,"returnOnEquity":45.2,"analystRating":"","recommendationKey":"none","numberOfAnalysts":15,"targetMeanPrice":22.85,"targetHighPrice":40.4,"targetLowPrice":13.75,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0,"institutionHeldPercent":3,"sharesOutstanding":171950364,"floatShares":508426998,"sharesShort":257002,"shortRatio":6.86,"shortPercentOfFloat":0.1,"epsTrailing":2.65,"epsForward":0.52,"revenuePerShare":3.19,"bookValue":7.2,"officers":[{"age":58,"name":"Mr. Chig Fung  Cheng BEc, CA","title":"Acting CEO, CFO & Executive Director"},{"age":66,"name":"Dr. Wei-Guo  Su B.Sc., Ph.D.","title":"CEO, Chief Scientific Officer & Executive Director (Leave of Absence)"},{"age":null,"name":"Ms. Yiling  Cui","title":"Executive VP & Head of Operations"},{"age":52,"name":"Dr. Xinhui  Hu Ph.D.","title":"Executive Vice President & Chief Technical Officer"},{"age":null,"name":"Mr. David  Ng","title":"Head of Investor Relations & Capital Strategies"},{"age":55,"name":"Mr. Charles George Rupert  Nixon","title":"Group General Counsel"},{"age":48,"name":"Mr. Kin Hung  Lee M.B.A.","title":"Senior Vice President of Corporate Management & Communications"},{"age":null,"name":"Ms. Selina  Zhang","title":"Senior Vice President of Global Human Resources"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.hutch-med.com","phone":"852 2121 8200"}}